CRIS Current Research Information System

RONDONI, MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.315
NA - Nord America 3.886
EU - Europa 3.393
SA - Sud America 234
Continente sconosciuto - Info sul continente non disponibili 234
AF - Africa 211
OC - Oceania 3
Totale 12.276
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.799
VN - Vietnam 1.317
IT - Italia 1.180
CN - Cina 1.068
SG - Singapore 979
GB - Regno Unito 645
SE - Svezia 339
DE - Germania 312
HK - Hong Kong 280
FR - Francia 185
BR - Brasile 165
IN - India 152
JP - Giappone 134
NL - Olanda 128
UA - Ucraina 125
RU - Federazione Russa 120
KR - Corea 116
IE - Irlanda 84
BD - Bangladesh 82
CI - Costa d'Avorio 69
FI - Finlandia 62
TG - Togo 54
CA - Canada 51
ZA - Sudafrica 51
EE - Estonia 40
CH - Svizzera 35
AR - Argentina 27
JO - Giordania 27
BE - Belgio 22
BG - Bulgaria 21
PL - Polonia 21
ID - Indonesia 20
ES - Italia 19
IQ - Iraq 18
PH - Filippine 18
TH - Thailandia 18
TW - Taiwan 18
SC - Seychelles 16
EU - Europa 15
MX - Messico 14
GR - Grecia 13
IR - Iran 13
EC - Ecuador 12
SA - Arabia Saudita 9
TR - Turchia 9
AT - Austria 7
CL - Cile 7
PK - Pakistan 7
PY - Paraguay 7
CR - Costa Rica 6
MY - Malesia 6
NG - Nigeria 6
RO - Romania 6
CZ - Repubblica Ceca 5
JM - Giamaica 5
LB - Libano 5
LT - Lituania 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
PT - Portogallo 4
VE - Venezuela 4
BY - Bielorussia 3
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
UZ - Uzbekistan 3
BA - Bosnia-Erzegovina 2
EG - Egitto 2
GY - Guiana 2
IL - Israele 2
MN - Mongolia 2
NE - Niger 2
NI - Nicaragua 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BO - Bolivia 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
GH - Ghana 1
GP - Guadalupe 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
LC - Santa Lucia 1
MA - Marocco 1
MM - Myanmar 1
MR - Mauritania 1
MT - Malta 1
Totale 12.056
Salva come PNG Salva come JPEG
Città #
Singapore 684
Southend 557
Ashburn 367
Ho Chi Minh City 352
Fairfield 309
Chandler 288
Hanoi 269
Hong Kong 258
Hefei 250
San Jose 221
Wilmington 170
Houston 166
Woodbridge 151
Seattle 144
Beijing 130
Dong Ket 130
Cambridge 123
Tokyo 123
Santa Clara 122
Ann Arbor 120
Bologna 111
Princeton 105
Seoul 99
Council Bluffs 98
Milan 91
Dallas 87
Jacksonville 84
Dublin 83
Los Angeles 82
Boardman 80
Abidjan 69
New York 67
Florence 65
Lauterbourg 65
Padova 56
Turin 55
Lomé 54
Rome 52
Westminster 51
Nanjing 49
Haiphong 42
Helsinki 42
Buffalo 32
Da Nang 32
Saint Petersburg 32
Shenyang 28
Berlin 27
Amman 26
Frankfurt am Main 26
Jinan 25
Munich 25
São Paulo 25
Ha Long 24
Bern 23
Biên Hòa 23
Bengaluru 21
Naples 21
Redondo Beach 21
Medford 20
Nanchang 20
San Diego 20
Shanghai 20
Hebei 19
Sofia 18
Bremen 17
Brussels 17
Changsha 17
Orem 17
Pavia 17
Toronto 17
Falls Church 15
Hải Dương 15
Thái Nguyên 15
Warsaw 15
Zhengzhou 15
Chicago 14
Guangzhou 14
Ninh Bình 14
Redmond 14
Jiaxing 13
Haikou 12
Montreal 12
Verona 12
Brooklyn 11
Catania 11
Mülheim 11
Norwalk 11
Palermo 11
Quận Bình Thạnh 11
Vũng Tàu 11
Baghdad 10
Düsseldorf 10
Lappeenranta 10
London 10
Pescara 10
Phoenix 10
San Francisco 10
Can Tho 9
Jakarta 9
Johannesburg 9
Totale 7.505
Salva come PNG Salva come JPEG
Nome #
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 885
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 667
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 317
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 306
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 221
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 220
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 215
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 214
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 213
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 212
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 210
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 208
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 204
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 193
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 188
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 183
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 181
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 180
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 178
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 176
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 176
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 173
Ultra-Deep Sequencing (UDS) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 171
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 170
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 170
Leucemia mieloide cronica: terapia molecolare 169
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia 169
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 167
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 167
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 162
Advanced mast cell disease: an Italian Hematological Multicenter experience 161
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 159
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. 159
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management 158
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 158
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 154
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. 152
Novel insights and therapeutic approaches in secondary AML 150
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study. 149
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. 147
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 145
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 144
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 143
Soft tissue and skeletal involvement in FIP1L1-PDGFR-A positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission 143
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 138
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 136
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 136
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly 133
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 133
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 133
HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING IDENTIFIES NOVEL UNIPARENTAL DISOMY AND FOCAL COPY NUMBER ALTERATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) 130
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders 128
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 128
Hypereosinophilic syndrome and molecularly targeted therapy. 127
Imatinib mesylate in the treatment of hematologic malignancies. 127
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 125
The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors. 125
Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant) 122
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience 116
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 111
Strategies in the treatment of acute myeloid leukemia. 111
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 108
null 104
Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients. 100
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. 99
Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia 85
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 81
null 76
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study 65
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation 62
Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series 50
The Italian Mastocytosis Registry: 6-year experience from a Hospital-Based Registry 49
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 39
Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers 12
Totale 12.276
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022912 0 17 63 117 94 84 17 66 37 75 187 155
2022/20231.365 160 233 52 173 66 96 50 65 224 28 171 47
2023/2024548 29 63 37 42 44 126 43 60 23 26 28 27
2024/20251.634 64 221 120 108 204 84 185 69 27 148 100 304
2025/20264.594 393 911 387 314 393 230 315 139 794 365 185 168
2026/2027265 132 133 0 0 0 0 0 0 0 0 0 0
Totale 12.276